UK pharma competitiveness Task Force results announced by Premier Blair

28 March 2001

UK Prime Minister Tony Blair has launched the publication of the finalreport of the Task Force, the joint chairmen of which were Health Minister Lord Philip Hunt and AstraZeneca chief executive Tom McKillop, that has been looking at the competitiveness of the UK-based pharmaceutical industry. Among action recommended by the report is a review of the National Institute for Clinical Excellence and streamlining procedures for animal experimentation.

Launching the report in the company of Dr McKillop and Lord Hunt, the Prime Minister said: "the UK pharmaceutical industry is one of our most important and most successful industries. Its products benefit people here and round the world and it makes a substantial contribution to our economic welfare."

"It is a truly global industry. Companies have a real choice about where to invest [and] the UK cannot rest on its laurels. We have to ensure the UK remains an attractive place for new investment. We set up the Task Force to see what needed to be done and to take action to maintain and develop the UK's competitive edge," Mr Blair stated. Thanking the co-chairmen for their efforts, he added: "the Task Force has done an excellent job. It shows what can be achieved when we work together on issues - both between government and industry and across government."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight